Study #2016-0889
An Open-label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects with Relapsed/Refractory Acute Myelogenous Leukemia, High-Risk Myelodysplastic Syndrome or T Acute Lymphoblastic Leukemia/Lymphoma
Study Status
Open
Treatment Agent
Daratumumab
Principal Investigator
Gautam Borthakur
Description
The goal of this clinical research study is to learn if daratumumab can help to control acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that is refractory (does not respond to treatment) or relapsed (comes back after being treated). The safety of this drug will also be studied.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: Daratumumab
Treatment Location: Only at MD Anderson
Sponsor: Janssen Scientific Affairs, LLC is the Supporter of this study.
Study Status
IRB Review and Approval Date: 10/27/2017
Recruitment Status: Open
Projected Accrual: N/A
Resources and Links
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase II
Physician name:
Gautam Borthakur
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789